Diamant Asset Management Inc. Purchases 402,164 Shares of ResMed Inc. $RMD

Posted by Geri Gentry on Jun 28th, 2026

Diamant Asset Management Inc. increased its holdings in shares of ResMed Inc. (NYSE:RMD – Free Report) by 21,166.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 404,064 shares of the medical equipment provider’s stock after buying an additional 402,164 shares during the quarter. Diamant Asset Management Inc.’s holdings in ResMed were worth $90,704,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. lifted its position in ResMed by 123.2% in the 3rd quarter. Landscape Capital Management L.L.C. now owns 49,017 shares of the medical equipment provider’s stock valued at $13,417,000 after acquiring an additional 27,060 shares in the last quarter. Nordea Investment Management AB increased its holdings in ResMed by 37.2% during the 4th quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock worth $262,027,000 after purchasing an additional 294,124 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of ResMed by 20.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 112,755 shares of the medical equipment provider’s stock valued at $30,847,000 after purchasing an additional 18,966 shares during the period. Intech Investment Management LLC raised its stake in shares of ResMed by 40.9% in the 3rd quarter. Intech Investment Management LLC now owns 31,299 shares of the medical equipment provider’s stock valued at $8,567,000 after purchasing an additional 9,083 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of ResMed by 13.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 979,087 shares of the medical equipment provider’s stock valued at $235,833,000 after purchasing an additional 118,296 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RMD shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $230.00 price objective (down from $286.00) on shares of ResMed in a research report on Wednesday, June 17th. Robert W. Baird set a $225.00 target price on ResMed in a research report on Friday, May 1st. Weiss Ratings cut ResMed from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Wells Fargo & Company reduced their price target on ResMed from $270.00 to $227.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Finally, Citigroup lowered their price objective on shares of ResMed from $340.00 to $270.00 and set a “buy” rating on the stock in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $270.82.

Read Our Latest Research Report on RMD

Insider Activity at ResMed

In related news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $193.96, for a total transaction of $968,054.36. Following the transaction, the chief executive officer directly owned 466,256 shares in the company, valued at approximately $90,435,013.76. The trade was a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total transaction of $450,000.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 16,973 shares of company stock valued at $3,580,754. 0.65% of the stock is currently owned by insiders.

ResMed Price Performance

NYSE:RMD opened at $200.49 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The stock’s 50-day simple moving average is $203.31 and its 200 day simple moving average is $231.18. The company has a market cap of $29.08 billion, a P/E ratio of 19.33, a P/E/G ratio of 1.28 and a beta of 0.80. ResMed Inc. has a 52-week low of $180.26 and a 52-week high of $293.81.

ResMed (NYSE:RMD – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, beating the consensus estimate of $2.79 by $0.07. The firm had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.42 billion. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.37 earnings per share. As a group, sell-side analysts forecast that ResMed Inc. will post 11.13 EPS for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th were paid a dividend of $0.60 per share. The ex-dividend date was Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed’s dividend payout ratio is currently 23.14%.

About ResMed

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.